Background
Intergroup 0099 — Phase III randomized trial. N=147 patients with locally advanced nasopharyngeal carcinoma (NPC), AJCC stage III or IV (T1–T4, N1–N3, M0), Karnofsky PS ≥60. Enrolled 1989–1995 at US intergroup institutions. Only 12% Asian patients — predominantly non-endemic NPC (WHO type I/II; different from Asian endemic NPC predominantly WHO type III). First trial to demonstrate survival benefit of CRT over RT alone in NPC; a landmark study that fundamentally changed treatment.
Interventions and follow up
Arm A: Concurrent CRT: RT 70 Gy + cisplatin 100 mg/m² D1, D22, D43 → adjuvant cisplatin 80 mg/m² D1 + fluorouracil 1000 mg/m²/day D1–4 q4wk × 3 cycle
Arm B: RT alone: 70 Gy standard fractionatio
Primary endpoint: PFS and OS
mFollow up: 60 month
Arm B: RT alone: 70 Gy standard fractionatio
Primary endpoint: PFS and OS
mFollow up: 60 month
Results
3-year PFS: 69% (CRT) vs 24% (RT alone), P<.001
3-year OS: 78% vs 47%, P=.005
5-year OS: 67% vs 37%, P=.001
Distant failure rate: 13% (CRT) vs 35% (RT alone)
3-year OS: 78% vs 47%, P=.005
5-year OS: 67% vs 37%, P=.001
Distant failure rate: 13% (CRT) vs 35% (RT alone)
Adverse events
Main adverse events: Grade 3–4 toxicities substantially higher in CRT arm: mucositis, nausea/vomiting, neutropenia. Treatment delays and hospitalizations more common. One patient in CRT arm died from toxicity. Adjuvant chemotherapy completion rate: 55% received all 3 cycles.
Conclusions
Cisplatin-based concurrent CRT followed by adjuvant cisplatin-fluorouracil dramatically improved PFS (69% vs 24%) and OS (78% vs 47%) at 3 years vs RT alone in LA NPC. Intergroup 0099 established concurrent CRT as the new standard of care for locally advanced NPC globally.
Key Limitations
Key Limitations: Predominantly enrolled non-Asian (non-endemic NPC) patients — generalizability to endemic Asian NPC (WHO type III, EBV-associated) was initially questioned. The large PFS benefit (69% vs 24%) reflects a particularly poor control arm in non-endemic NPC, possibly overstating the magnitude of CRT benefit in Asian cohorts. Adjuvant chemotherapy completion rate was poor (55%), raising questions about whether concurrent or adjuvant component drove the benefit. Subsequent Asian trials (MAC-NPC meta-analysis) confirmed concurrent cisplatin benefit but showed adjuvant chemotherapy added toxicity without proportional benefit.
Clinical Context
Intergroup 0099 was practice-changing globally — concurrent cisplatin + RT became the standard of care for LA NPC after 1998. Subsequent trials refined the approach: concurrent cisplatin + IMRT is now standard. The role of adjuvant chemotherapy remained debated; Sun 2016 and others have evaluated induction chemotherapy instead. EBV DNA and ctDNA monitoring have emerged for response assessment and risk stratification in endemic NPC. NCCN and ESMO recommend concurrent cisplatin + IMRT for LA NPC, with adjuvant or induction chemotherapy as category 2 additions.
References
References: Al-Sarraf M et al, JCO 1998 (primary)